High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy

Journal of Medical Virology

Volumn 85, Issue 5, 2013, Pages 893-898

  Harvala, Heli ^a   Stewart, Camilla ^a   Muller, Kate ^a   Burns, Sheila ^a   Marson, Lorna ^a   Macgilchrist, Alastair ^a   Johannessen, Ingolfur ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INFECTION RISK; LIVER GRAFT; MORTALITY; ORGAN TRANSPLANTATION; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CYTOMEGALOVIRUS;

EID: 84875636414     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23539     Document Type: Article

References (29)

1. Andrews PA, Emery CV, Newstead C. 2011. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV disease after solid organ transplantation. Transplantation 92:1181-1187.
2. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. 2007. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transplant 13:1703-1709.
3. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. 2008. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46:840-846.
4. Blumberg EA, Hauser IA, Stanisic S, Mueller E, Berenson K, Gahlemann CG, Humar A, Jardine AG. 2010. Prolonged prophylaxis with valganciclovir is cost effective in reducing post-transplant cytomegalovirus disease within the United States. Transplantation 90:1420-1426.
5. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. 2001. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366-1371.
6. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 2006. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 81:1106-1111.
7. Emery VC, Asher K, de Juan Danjuan C. 2012. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. J Clin Virol 54:125-129.
8. Fishman JA, Rubin RH. 1998. Infection in organ-transplant recipients. N Engl J Med 338:1741-1751.
9. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667.
10. Freeman RB. 2009. The indirect effects of cytomegalovirus infection. Am J Transplant 9:2453-2458.
11. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, Moorhead J, Griffiths PD. 1988. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2:132-135.
12. Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. 2001. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 71:1609-1615.
13. Helanterä I, Lautenschlager I, Koskinen P. 2009. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 24:316-320.
14. Helanterä I, Kyllönen L, Lautenschlager I, Salmela K, Koskinen P. 2010. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 10:2026-2032.
15. Hughes D, Hafferty J, Fulton L, Friend P, Devaney A, Loke J, Welsh KI, Handa A, Klenerman P. 2008. Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients. J Clin Virol 41:92-95.
16. Humar A, Washburn K, Freeman R, Paya CV, Mouas H, Alecock E, Razonable RR, PV16000 Study Group. 2007. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transplant 13:1422-1427.
17. Humar A, Snydman D, AST Infectious Diseases Community of Practice. 2009. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9:S78-S86.
18. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. 2010a. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10:1228-1237.
19. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JAL, Farhan M, Peeters P. 2010b. Extended valganciclovir prophylaxis in D+R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study. Transplantation 90:1427-1431.
20. Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA. 2009. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation 88:77-82.
21. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. 2009. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 4:e5512.
22. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. 2008. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 8:975-983.
23. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. 2010. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795.
24. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M. 2004. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78:1390-1396.
25. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, Kuhr CS, Levy AE, Perkins JD, Reyes JD, Boeckh M. 2006. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81:1645-1652.
26. Ljungman P, Griffiths P, Paya C. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094-1097.
27. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group. 2004. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611-620.
28. Rubin RH. 2001. Cytomegalovirus in solid organ transplantation. Transp Infect Dis 3:1-5.
29. Singh N. 2006. Cytomegalovirus infection in solid organ transplant recipient: New challenges and their implication for preventive strategies. J Clin Virol 35:474-477.